Daniel Furst, MD

Daniel Furst, MD
 

Professor of Rheumatology
Carl M. Pearson Chair of Rheumatology
Director of Interventional Therapeutics
University of California, Los Angeles Medical Center for Health Sciences
Los Angeles, CA

What evidence and clinical guidance is offered by trials evaluating the role, safety, and efficacy of IL-6 targeting agents in the setting of RA? Video

What evidence and clinical guidance is offered by trials evaluating the role, safety, and efficacy of IL-6 targeting agents in the setting of RA?

What evidence and clinical guidance is offered by trials evaluating the role, safety, and efficacy of IL-6 targeting agents in the setting of RA?
Daniel Furst, MD

Daniel Furst, MD

In general, how rapid is the onset of action of IL-6 inhibitors and can these agents be used as monotherapy? Video

In general, how rapid is the onset of action of IL-6 inhibitors and can these agents be used as monotherapy?

In general, how rapid is the onset of action of IL-6 inhibitors and can these agents be used as monotherapy?
Daniel Furst, MD

Daniel Furst, MD

Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors -- established and soon-to-market -- will reflect a class effect, or do you feel they will be clinically differentiated? Video

Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors -- established and soon-to-market -- will reflect a class effect, or do you feel they will be clinically differentiated?

Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors — established and soon-to-market — will reflect a class effect, or do you feel they will be clinically differentiated?
Daniel Furst, MD

Daniel Furst, MD

In what patient subsets (RA biomarkers, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Video

In what patient subsets (RA biomarkers, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective?

In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Do they seem to optimize outcomes when they are used earlier in the natural history of the disease?
Daniel Furst, MD

Daniel Furst, MD

When a suboptimal clinical response is encountered with TNFIs or interleukins antagonists, what other strategies may be effective? How are these decisions made and where might an IL-6 inhibitor fit? Video

When a suboptimal clinical response is encountered with TNFIs or interleukins antagonists, what other strategies may be effective? How are these decisions made and where might an IL-6 inhibitor fit?

When a suboptimal clinical response has been encountered with TNFIs or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an IL-6 inhibitor fit?
Daniel Furst, MD

Daniel Furst, MD

What are the advantages of targeting the IL-6 cytokine system? Please discuss as it relates to stabilization of chronic disease, global symptom scores, and ability to mitigate rapidly progressive RA. Video

What are the advantages of targeting the IL-6 cytokine system? Please discuss as it relates to stabilization of chronic disease, global symptom scores, and ability to mitigate rapidly progressive RA.

What are the possible advantages of targeting the IL-6 cytokine system? Please discuss as it relates to stabilization of chronic disease, effects of global symptom scores, and ability to mitigate rapidly progressive RA.
Daniel Furst, MD

Daniel Furst, MD